Presentation Public School

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Interim, American Society of Clinical Oncology, Therapy, CRS, DL, DCR, DLT, DL 2, Oncology, Harvard Medical School, Presentation Public School, ASCO, TAC, MD, Patient, GEJ, Annual general meeting, Toxic epidermal necrolysis, ICU, ORR, News, Safety, Dana–Farber Cancer Institute, Pharmaceutical industry, Medicine

"We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.

Key Points: 
  • "We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with HER2-positive gastric and esophageal cancers."
  • Interim results from the Phase I TACTIC-02 study suggest a highly favorable safety profile for TAC-01 HER2 treatment with the potential of being an outpatient procedure.
  • A copy of the presentations will be available after the closure of the meeting, under the Presentations & Publications tab of the News & Resources section of the Company's website .

Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
American Society of Clinical Oncology, Therapy, HER2, Cancer, Oncology, Presentation Public School, Harvard Medical School, ASCO, Dana–Farber Cancer Institute, MD, Patient, Annual general meeting, Poster, Abstract, News, Medical imaging, Medicine

The presentation by Benjamin L. Schlechter, MD, from Harvard Medical School and a Senior Physician in Gastrointestinal Oncology at the Dana-Farber Cancer Institute, will highlight updated clinical data from the ongoing Phase I/II trial of TAC01-HER2 ( NCT04727151 ) in patients with relapsed or refractory solid tumors.

Key Points: 
  • The presentation by Benjamin L. Schlechter, MD, from Harvard Medical School and a Senior Physician in Gastrointestinal Oncology at the Dana-Farber Cancer Institute, will highlight updated clinical data from the ongoing Phase I/II trial of TAC01-HER2 ( NCT04727151 ) in patients with relapsed or refractory solid tumors.
  • "We are excited to present the latest clinical data from our Phase I/II trial of TAC01-HER2 in refractory solid tumors at the upcoming ASCO meeting as a poster and a poster discussion.
  • The availability of updated clinical data will offer remarkable insights into the potential of TAC01-HER2 as a targeted therapy for patients who are refractory to existing HER2 targeted therapies," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.
  • A copy of the presentations will be available after the closure of the meetings, under the Presentations & Publications tab of the News & Resources section of the Company's website .

Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
Cancer, AACR, Presentation Public School, HER2, News, Abstract (summary), Patient, New Resource Bank, Safety, White, Therapy, Pharmaceutical industry

The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Key Points: 
  • The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
  • Further, we will present new preclinical data from our allogeneic T cell-based products in development demonstrating their potential to avoid graft versus host disease."
  • Abstracts are currently available on the AACR website .
  • A copy of the presentations will also be available after the closure of the meeting on April 19, under the Presentations & Publications tab of the News & Resources section of the Company's website .

Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

Retrieved on: 
Wednesday, February 22, 2023
Safety, Pediatrics, Central nervous system, Infant, Perelman School of Medicine at the University of Pennsylvania, Syndrome, University, Week, Vineland Adaptive Behavior Scale, Glycosaminoglycan, University of Pennsylvania, Presentation Public School, Bayley Scales of Infant Development, Biologics license application, GAG, MPS II, Hunter syndrome, Cohort, Acquisition, CSF, Biomarker, Socialization, ERT, Fluid mechanics, Patient, CNS, Immunosuppression, SD, Plasma, II, HS, MPS, Urine, Șaeș, Phase, Communication, Pharmaceutical industry, Vaccine, Medical imaging

"GAGs measured in CSF, specifically heparan sulfate, reflect disease manifestations in the CNS and are a direct cause of disease pathophysiology.

Key Points: 
  • "GAGs measured in CSF, specifically heparan sulfate, reflect disease manifestations in the CNS and are a direct cause of disease pathophysiology.
  • "The data presented today are encouraging and continue to show the potential of a one- time gene therapy to provide meaningful, durable clinical benefits to the MPS II community.
  • Data presented were from the Phase I/II portion of the CAMPSIITE trial in which the primary endpoint is to evaluate the safety of RGX-121.
  • Dr. Ficicioglu will share this data in a platform presentation at the WORLDSymposium Sunday, February 26, 2023, at 9 a.m.

Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022

Retrieved on: 
Thursday, November 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, TAC, GPC3, Immunologic Constant of Rejection, IND, Kinetics, GUCY2C, Presentation Public School, Annual general meeting, EST, Immunotherapy, Lonza, Neoplasm, Colorectal cancer, Technology, CD8, Society for Immunotherapy of Cancer, Flow cytometry, Safety, Cancer, Toxicity, Cell, Stomach, Patient, Therapy, News, Society, SITC, Vaccine, Cain (band)

Data was shared in three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held virtually and in-person in Boston.

Key Points: 
  • Data was shared in three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held virtually and in-person in Boston.
  • The data showed that CLDN18.2-TAC T and GUCY2C-TAC T could be an effective treatment for hard to treat solid tumors."
  • Triumvira announced updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) for the treatment of gastric cancer.
  • The data continue to demonstrate that CLDN18.2-TAC T effectively eliminates CLDN18.2-expressing gastric cancer cells in vitro and in vivo.

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, October 27, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Stomach, TAC, GPC3, Society, GUCY2C, Society for Immunotherapy of Cancer, Annual general meeting, Presentation Public School, News, Immunotherapy, Journal, Technology, EST, Patient, Lonza, Cancer, IND, SITC, Synthetic immunology, 2021 Essex County Council election, JITC, Therapy, Safety, Vaccine

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually.
  • Full abstract content will be available online in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7, 2022 at 8:00 a.m. EST.
  • Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology.
  • Triumviras pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years.

REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy

Retrieved on: 
Thursday, October 27, 2022
Technology, Medicine, Duke University School of Medicine, AAV, Diabetic retinopathy, Presentation Public School, Eye, CA, Webcast, Therapy, Patient, MD, Company, Phase, Department, Diabetes, Associate, Retina, Pharmaceutical industry, Disease, Ophthalmology

The Company will host a conference call on Thursday, November 3, 2022, at 8:30 a.m.

Key Points: 
  • The Company will host a conference call on Thursday, November 3, 2022, at 8:30 a.m.
  • ET to discuss its financial results for the quarter ended September 30, 2022, recent operational highlights and this interim data.
  • A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion.
  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Technology, New Resource Bank, Abstract (summary), News, TAC, Synthetic immunology, European Society for Medical Oncology, EDT, ESMO, Presentation Public School, Congress, HER2, Paris Expo Porte de Versailles, Therapy, Oncology, CEST, TCR, Patient, Vaccine

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).

Key Points: 
  • TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
  • Location: Paris Expo Porte de Versailles, Hall 4
    Abstracts will be published online on the ESMO website at 12:05 a.m. CEST on Sept. 5, 2022 (6:05 p.m. EDT on Sept. 4, 2022).
  • Triumvira Immunologics, Inc. (Triumvira) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.
  • The companys proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies.